Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiagabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 known ✓ | P30531 | 10/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiagabine SCHEMBL342814 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL34653 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL41860 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL18496408 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL7346237 | 0.99 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL3958156 | 0.99 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL17493682 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL5164417 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL1527642 | 0.98 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| SCHEMBL9773551 | 0.95 | SLC6A1 (0.90) | SLC6A1PTGS1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9649297-B2 | Treatment of ADHD | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2017-05-16 | — | — | US | disclosed |
| US-20150313877-A1 | TREATMENT OF ADHD | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2015-11-05 | — | — | US | disclosed |
| US-8957099-B2 | Treatment of ADHD | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2015-02-17 | — | — | US | disclosed |
| WO-2013074320-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2505197-A1 | Treatment of ADHD | Gosforth Centre (Holdings) Pty Ltd (AU) | 2012-10-03 | — | — | EP | disclosed |
| US-20100087422-A1 | TREATMENT OF ADHD | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-04-08 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009124755-A1 | COMPOUNDS WITH NOVEL MEDICAL USES AND METHOD OF IDENTIFYING SUCH COMPOUNDS | EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) | 2009-10-15 | — | — | WO | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| WO-2008079727-A2 | COMPOSITIONS COMPRISING AN PAN-ALPHA-2 RECEPTOR AGONIST AND AN ANTICONVULSANT FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2005092886-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS FORM OF TIAGABINE | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | SLC6A1 1403/4885PTGS1 1133/4885PDE4A 2900/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | SLC6A1 1403/4885PTGS1 1133/4885PDE4A 2900/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | SLC6A1 1250/4885PTGS1 521/4885PDE4A 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.